MBLAC2

Across TCGA pan-cancer cohorts, MBLAC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MBLAC2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MBLAC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBLAC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where MBLAC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.712	0.993	.024	5	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	3	view →
CCRCC	OS	Median	All	0.953	0.691	.040	1	view →
GBM	DFS	Quartile	All	0.875	0.592	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MBLAC2–LUAD (DFS)

Open the LUAD breakdown →